Stock of the Day

March 14, 2024

Spero Therapeutics (SPRO)

$1.22
+$0.02 (+1.7%)
Market Cap: $69.88M

About Spero Therapeutics

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Today's Trend

Spero Therapeutics, Inc. (NASDAQ: SPRO) shares rose today after multiple reports confirmed a major win in its GSK-partnered Phase 3 trial for tebipenem HBr in complicated urinary tract infections (cUTIs), triggering heightened investor interest and bullish trading activity.

  • Independent Data Monitoring Committee recommended an early stop for efficacy in the PIVOT-PO Phase 3 cUTI trial, setting the stage for an FDA filing in H2 2025
  • If approved, tebipenem HBr would be the first oral carbapenem antibiotic for US patients, addressing ~2.9 million cUTI cases annually
  • SPRO stock surged after news that the GSK-partnered UTI drug hit its primary endpoint ahead of schedule
  • Unusually large options volume—1,962 call options traded versus a typical 48—signals strong bullish sentiment
  • Named among MarketBeat’s “Best Penny Stocks To Watch” for May 28, highlighting its small-cap volatility
  • Multiple trading halts due to Limit Up/Limit Down (LULD) pauses amid rapid price moves
← Previous Stock of the DayNext Stock of the Day →